Skip To Main Content
Lin-Quan Tang on Muck Rack

Lin-Quan Tang

As seen in: Nature, BMC Cancer, JAMA Oncology, EClinicalMedicine, The Lancet, European Journal of Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Lin-Quan

Contact Lin-Quan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Diagnostic Performance of Anti–Epstein-Barr Virus BNLF2b in Suspected Nasopharyngeal Carcinoma

|
By Su-Chen Li, Shi-Ji Wu, Min-Zhong Tang, Ting-Dong Li, Ning-shao Xia, Hai-Qiang Mai, Ming-Fang Ji, Lin-Quan Tang, Li Yuan Verified, Xia Yu, Hui-jun Li, Ying-Ying Lin, Wan-Li Liu, Shan Xing, Yan-Song Chen, Ya-xian Wu, Li-Ting Liu, Shan-Shan Guo, Xin Li, Min-Yi Fu, Hao Tang, Jin Ma, Tian-Sheng Gao, Xiao-Fei Lv, Jing Zhong, Zhi-ming Li, Ming Song, Shu-Wei Chen, Xing Lv, Wei-Xiong Xia, Yi-Jun Hua, Lin Wang, Qi YANG, Xiong Zou, Hu Liang, Jing-Jing Miao, Sai-Lan Liu, Xiao-Yun Li, Xue-Song Sun, Jun Zhang, Fu-Gui Li, Zhen-Zhou Xiao, Biao-Hua Wu, Xiu-Fang He, Guo-Xian Long, Jin-Bin Ye, Lu-Jun Li, Qiao-Juan Guo, Xue-Hong Xiao, Shao-Lu Lu, Rui-Ling Xie, Sheng-Xiang Ge
| JAMA Oncology Verified
Diagnostic Performance of Anti–Epstein-Barr Virus BNLF2b in Suspected Nasopharyngeal Carcinoma Key Points Question Which Epstein-Barr virus (EBV)–related biomarkers provide the most reliable diagnostic performance for suspected nasopharyngeal carcinoma (NPC) in outpatient settings?
Open in Who Shared Issue with article?

Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trial

|
By Li-Ting Liu, Xue-Song Sun, Xiao-Yun Li, Ling Guo, Hao-Yuan Mo, Shan-Shan Guo, Sai-Lan Liu, Ying Huang, Dong-Hua Luo, Rui Sun, Ji-Bin Li, Qing Liu, Pan Wang, Yu-Jing Liang, Jie Chen, Hui Cheng, Wei-Xiong Xia, Fang Qiu, Jin-Hao Yang, Qi YANG, Dong-Xiang Wen, Jin-Jie Yan, Chong Zhao, Qiu-Yan Chen, Lin-Quan Tang, Hai-Qiang Mai, Ting-Ting Quan, Guo-Dong Jia, Yi-Fu Li
| Nature Verified
Abstract Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) is the standard treatment for locoregionally advanced nasopharyngeal carcinoma (LA-NPC); however, patients with a suboptimal response to IC, defined as detectable Epstein–Barr virus DNA and/or stable or progressive disease after IC, remain at high risk of treatment failure.
Open in Who Shared Issue with article?

Epstein-Barr virus DNA-guided chemoradiotherapy for patients with low-risk locoregionally advanced nasopharyngeal carcinoma: a secondary 5-year follow-up analysis of an open-label, randomised controlled, phase 2 non-inferiority trial - eClinicalMedicine

|
By Hai-Qiang Mai, Lin-Quan Tang, Liang-Ji Li
| EClinicalMedicine Verified
Keywords Nasopharyngeal carcinoma De-intensified chemoradiotherapy Randomised trial Long-term outcomes Evidence before this study Prior evidence derived from systematic literature reviews (PubMed, Embase, Cochrane; from database inception to June 5, 2025) established that three cycles of concurrent cisplatin (DDP, 100 mg/m2 q3w) with radiotherapy constituted the guideline-recommended standard for stage II–IVA nasopharyngeal carcinoma (NPC), despite high toxicity rates reducing treatment...
Open in Who Shared Issue with article?
See all 7 articles